Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 7/2018

01-07-2018 | Review Article

Effects of Shengmai injection add-on therapy to chemotherapy in patients with non-small cell lung cancer: a meta-analysis

Authors: Baoqi Duan, Jinsong Xie, Qinglin Rui, Wenxi Zhang, Zhaoqing Xi

Published in: Supportive Care in Cancer | Issue 7/2018

Login to get access

Abstract

Purpose

Shengmai injection (SMI) has shown promising outcomes in the management of non-small cell lung cancer (NSCLC). This meta-analysis aimed to investigate the add-on effects of SMI to chemotherapy in NSCLC patients.

Methods

A comprehensive literature search was performed in the Cochrane Library, PubMed, Embase, CNKI, VIP, and Wanfang up to December 2017. Only randomized controlled trials (RCTs) evaluating SMI in combination with chemotherapy versus chemotherapy alone in NSCLC patients were eligible. The outcome measures were quality of life, chemotherapy-induced grade 3/4 myelosuppression or gastrointestinal reactions, and objective tumor response (equals complete response plus partial response). Pooled risk ratio (RR) with 95% confidence interval (CI) was used to evaluate dichotomous and continuous outcome, respectively.

Results

A total of 15 RCTs were included and analyzed. Meta-analysis showed that SMI combined with chemotherapy was associated with a significant improvement in Karnofsky Performance Status (RR 2.36; 95% CI 1.50–3.96) compared with the chemotherapy alone. Moreover, adjunctive treatment with SMI significantly reduced grade 3/4 myelosuppression (RR 0.61; 95% CI 0.46–0.81) and gastrointestinal reactions (RR 0.64; 95% CI 0.46–0.90). However, there was no significant difference in objective tumor response (RR 1.17; 95% CI 0.99–1.37) between two groups.

Conclusions

SMI add-on therapy appeared to be more effective in improving quality of life and reducing chemotherapy-induced adverse effects. However, more well-designed RCTs are warranted to confirm the findings of this meta-analysis because of the suboptimal methodological quality of the included trials.
Appendix
Available only for authorised users
Literature
1.
2.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology risk factors, treatment, and survivorship. Mayo Clin Proc 83(5):584–594CrossRefPubMed
3.
Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, Paz-Ares L (2017) Lung cancer: current therapies and new targeted treatments. Lancet 389(10066):299–311CrossRefPubMed
4.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D’Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2017) Non-small cell lung Cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 15(4):504–535CrossRef
5.
6.
Jiao L, Dong C, Liu J, Chen Z, Zhang L, Xu J, Shen X, Che J, Yang Y, Huang H, Li H, Sun J, Jiang Y, Mao Z, Chen P, Gong Y, Jin X, Xu L (2017) Effects of Chinese medicine as adjunct medication for adjuvant chemotherapy treatments of non-small cell lung cancer patients. Sci Rep 7:46524CrossRefPubMedPubMedCentral
7.
Han Y, Wang H, Xu W, Cao B, Han L, Jia L, Xu Y, Zhang Q, Wang X, Zhang G, Yu M, Yang G (2016) Chinese herbal medicine as maintenance therapy for improving the quality of life for advanced non-small cell lung cancer patients. Complement Ther Med 24:81–89CrossRefPubMed
8.
Jiang Y, Liu LS, Shen LP, Han ZF, Jian H, Liu JX, Xu L, Li HG, Tian JH, Mao ZJ (2016) Traditional Chinese medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: a randomized controlled trial. Complement Ther Med 24:55–62CrossRefPubMed
9.
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269 W264CrossRefPubMed
10.
Schag CC, Heinrich RL, Ganz PA (1984) Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 2(3):187–193CrossRefPubMed
11.
Ramalingam S, Belani CP (2002) Doublet chemotherapy for advanced non-small cell lung cancer. Clin Lung Cancer 4(1):13PubMed
12.
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207–214CrossRefPubMed
13.
Zhou GF, Li AJ (2003) Shengmai injection treatment for chemotherapy-reduced adverse reaction in non-small cell lung cancer 30 cases of patients. CJITWM 23(3):231–232
14.
Li GX (2005) Clinical observation of Shengmai injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer. JETCM 14(3):233–234
15.
Wang R, Wang ZX, Wang QC (2006) Shengmai injection combined with gemcitabine plus cisplatin cure advanced NSCLC. Suzhou Univ J Med Sci 26(4):631–633
16.
Liang CW (2007) Clinical study on the treatment of advanced NSCLC with Shengmai injection combined with chemotherapy. J Anhui TCM Coll 26(3):15–18
17.
Yao JT, Wang YZ, Zhang YJ, Wu HM, Zhao Z (2007) Clinical observation of Shengmai injection combined chemotherapy in advanced lung cancer. J Mod Oncol 15(8):1119–1120
18.
Zhang QH (2008) Clinical observation of adjunctive treatment with Shengmai injection in non small cell lung cancer. Mod J Integr Tradit Chin West Med 17(24):3827–3828
19.
Sun DB, Han Y (2009) The VEGF levels after pulse-activating ingection combined with interventional chemotherapy for non-small cell lung cancer. J Xinjiang Med Univ 32(9):1282–1284
20.
Chen QS, Chen Y, Yang ZJ, Liu JB, Pei RQ (2011) The effect on quality of life to advanced stage non-small cell lung cancer patient treated with Shengmai injection combined chemotherapy. China J Chin Med 26(1):13–15
21.
Lu XA (2011) Effect of Shengmai injection combined with chemotherapy on the quality of life and immune function in patients with advanced non-small cell lung cancer. Shaanxi J Tradit Chin Med 32(4):389–391
22.
Bao YH (2011) Effect of Shengmai injection on the quality of life of patients with advanced non-small cell lung cancer receiving chemotherapy. Chin J Clin Res 24(11):1037–1038
23.
Yang ZJ, Deng CM, Qiu YH, Mo BS (2012) Shengmai injection combined with NP regimen in the treatment of 30 cases of advanced non-small cell lung cancer. World Health Dig Med Periodieal 9(26):124–125
24.
Wu Q, He X (2012) Clinical observation of Shengmai injection combined with chemotherapy in the treatment of middle to advanced lung cancer. Chin J Tradit Med Sci Technol 19(1):71–72
25.
Wang DJ (2012) Efficacy of Shengmai injection combined with TP regimen in the treatment of advanced non-small cell lung cancer. Jilin Med J 33(11):2315–2316
26.
Liu JY, Liu BY, Liu Y (2014) Clinical efficacy of Shengmai injection combined with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer. China J Pharm Econ 9(11):211–212
27.
Zhang CM (2016) Effect of Shengmai injection combined with chemotherapy in the treatment of patients with advanced non-small cell lung cancer. Chin Prim Health Care 30(7):92–93
28.
Mannion E, Gilmartin JJ, Donnellan P, Keane M, Waldron D (2014) Effect of chemotherapy on quality of life in patients with non-small cell lung cancer. Support Care Cancer 22(5):1417–1428CrossRefPubMed
29.
Li Q, Liu H (2005) Pharmacological action and clinical application of Shengmai injection. Med Recapitulate 11(10):950–952
Metadata
Title
Effects of Shengmai injection add-on therapy to chemotherapy in patients with non-small cell lung cancer: a meta-analysis
Authors
Baoqi Duan
Jinsong Xie
Qinglin Rui
Wenxi Zhang
Zhaoqing Xi
Publication date
01-07-2018
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 7/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4167-4

Other articles of this Issue 7/2018

Supportive Care in Cancer 7/2018 Go to the issue

Original Article

Changes in upper extremity function, ADL, and HRQoL in colorectal cancer patients after the first chemotherapy cycle with oxaliplatin: a prospective single-center observational study

Original Article

Integrative medicine and the oncology patient: options and benefits

Original Article

Management and survival analysis of elderly patients with a cancer in the digestive system who refused to receive anticancer treatments

Original Article

Quality of life trajectories during the first year following hematopoietic cell transplantation: an inception cohort study

Original Article

A multi-center survey on dietary knowledge and behavior among inpatients in oncology department

Original Article

Impact of opioid use on health care utilization and survival in patients with newly diagnosed stage IV malignancies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits